Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis.
This article reviews the effects of DMARDs (including biologic agents) on bone metabolism in rheumatoid arthritis (RA). At present there is no evidence that methotrexate, at least at dosages ranging from 5 to 20 mg/week, negatively affects bone mass as measured by DXA (BMD) as documented in both cross-sectional and longitudinal studies. Most studies of cyclosporine (CyA) use reporting a reduction in erosions and joint damage with no adverse effects on bone, did not measure BMD; CyA treatment is associated with a dose-dependent increase of bone turnover as well as a decrease in both animal and human studies; however, its use in RA setting at a dose < or =5 mg/Kg/ day has so far not been associated with clinical relevant adverse effects on bone metabolism. Anti-TNF-alpha agents, infliximab reduced markers of bone turnover in two longitudinal studies. Data on BMD are not available in RA; nevertheless, an increase in BMD has been documented in spondyloarthropathies with infliximab and etanercept. No clinical data concerning BMD are available on leflunomide as well as on the newer biologic agents (adalimumab, rituximab, anakinra).
Di Munno
O
O
Department of Internal Medicine, U O Reumatologia, University of Pisa, Pisa, Italy. odimunno@int.med.unipi.it
Delle Sedie
A
A
Rossini
M
M
Adami
S
S
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D016572:Cyclosporine / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000069285:Infliximab; D008727:Methotrexate / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D016572:Cyclosporine; D000069285:Infliximab; D008727:Methotrexate